4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021
4d Pharma PLC (DDDD.L) $30 Million Credit Facility with Oxford Finance
Leeds, UK, July 29, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
4d Pharma PLC (DDDD.L) Passing of Chief Financial Officer John Beck
Leeds, UK, July 26, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
4d Pharma PLC (DDDD.L) Publication – LBP improves activity of CAR-T
4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T
Microsaic Systems (MSYS.L) Trading update for H1 2021
Unaudited revenues up 594% on H1 2020 and 52% on H1 2019, reflecting new business model
Microsaic Systems (MSYS.L) Development of real-time monitoring solution
Microsaic demonstrates real-time monitoring for scaling biotherapeutic production Automated system maintains high quality while allowing rapid scaling to large volumes.
4d Pharma PLC (DDDD.L) Conference presentation on LBP Manufacturing
4D pharma to Present at the Microbiome Movement Drug Development Summit
4d Pharma PLC (DDDD.L) Presentations on MRx0518 at SITC 2020
4D pharma announces three presentations at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020
4d Pharma PLC (DDDD.L) Topline Results for Blautix® phase II trial
Positive trends seen in primary efficacy endpoint of the study of overall response in both IBS-C and IBS-D subgroups
Braveheart Inv Group (BRH.L) Holding in Phasefocus increased and other matters
Braveheart (AIM: BRH), the fund management and strategic investment group, is pleased to announce that it has conditionally acquired 22,145 shares in Phasefocus Holdings Limited (“Phasefocus”) from Synergy Investments Limited
N4 Pharma Plc (AIM:N4P) Warrants cash to be used to accelerate vaccine plans
13 Dec 2017: The Company announces that it has received an exercise notice for the exercise of 2,071,429 warrants over ordinary shares of 0.4p each at an exercise price of